PD and PK Profiles of Switching Between Cangrelor and Ticagrelor Following Ticagrelor Pre-treatment
Status:
Recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
Cangrelor is an intravenous P2Y12 inhibitor utilized as a bridge to achieve adequate platelet
inhibition until oral P2Y12 inhibitors achieve their full antiplatelet effects in patients
undergoing coronary stenting. Although in this setting the potent oral P2Y12 inhibitor
ticagrelor is commonly utilized, there is very limited data on the optimal approach for
switching between these therapies. The methodological approach for this assessment should
rely on comprehensive pharmacodynamics (PD) investigations aimed to assess levels of P2Y12
receptor inhibition, pharmacokinetic (PK) investigations to assess systemic levels of the
drug/drug metabolite, and mechanistic investigations by assessment of levels of P2Y12
receptor gene expression. The overarching aim of this investigation is to rule out a
drug-drug interaction when ticagrelor is administered prior to cangrelor infusion.
Phase:
Phase 4
Details
Lead Sponsor:
University of Florida
Collaborators:
Scott R MacKenzie Foundation Scott R. MacKenzie Foundation